Search Results
Edoxaban versus dalteparin for venous thromboembolism associated with cancer
Edoxaban for Cancer-Associated Venous Thromboembolism
ASH 2017: Gary E. Raskob: Edoxaban vs. Dalteparin for VTE in Cancer: Hokusai VTE-Cancer Study
The Hokusai VTE-Cancer Study: objectives and design
Alok Khorana: Rivaroxaban Prevents Cancer-Associated VTE
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
Direct Oral Anticoagulants Compared With Dalteparin for TX of Cancer-Associated Thrombosis
Benefits of apixaban among venous thromboembolism patients with active cancer
Edoxaban for the treatment of cancer-associated venous thromboembolism
How is cancer-related venous thromboembolism treated in real world practice?
The use of anticoagulants in cancer-associated venous thromboembolism
The Hokusai VTE-Cancer Study: the importance of improving VTE treatment
